Search
elagolix (Orilissa)
Indications:
- endometrosis pain
Dosage:
- 150 mg PO QD for up to 24 months
- 200 mg PO BID for up to 6 months
Adverse effects:
- dose-dependent decrease in bone mineral density
- osteopenia, osteoporosis
Mechanism of action:
- gonadotropin-releasing hormone antagonist
General
hormone antagonist
endocrine agent
Database Correlations
PUBCHEM correlations
References
- Brooks M.
FDA Clears Elagolix (Orilissa) for Endometriosis Pain.
Medscape - Jul 24, 2018.
https://www.medscape.com/viewarticle/899731